IDYA

← Markets

IDYAIDEAYA Biosciences, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Fri, Aug 28
5:00 AMprnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Wed, Aug 19
5:00 AMYahooIDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
Wed, Aug 5
3:12 PMYahooThe Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership
Tue, Aug 4
5:00 AMYahooIDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Mon, Jul 27
5:00 AMYahooIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
Fri, Jul 17
8:00 AMYahooIDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
Wed, Jun 17
5:00 AMYahooIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Mon, Jun 15
5:00 AMYahooIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Thu, Jun 11
5:20 AMYahooIdeaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
Sat, Jun 6
5:08 AMYahooWhat IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders
Wed, Jun 3
5:00 AMYahooIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
Mon, Jun 1
10:00 AMYahooIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO